Where Do Potent P2Y12 Inhibitors Fit Into Current Practice? - Chronic Coronary Syndrome (CCS)
Published: 03 October 2022
-
Views:
24637
-
Likes:
7
-
Views:
24637
-
Likes:
7
-
15m 51sPart 3 Prevention in Diabetes
-
18m 5sPart 4 Long-term Management of CCS
-
9m 52sPart 5 Q&A and Discussion
-
12m 29sPart 1 Unmet Needs in CCS Marc P Bonaca, Philippe Gabriel Steg, Deepak L Bhatt
Overview
This broadcast series 'Where Do Potent P2Y12 Inhibitors Fit Into Current Practice?' will reappraise potent P2Y12 inhibitors, as evidence accumulates to support their broader use. At this juncture, there is still some uncertainty around patient selection, initiation and long-term management.
The second broadcast in this series, focused on Chronic Coronary Syndrome (CCS). In this on-demand version of the live broadcast, Radcliffe Medical Education brings together a global faculty of experts in the field to look at current guidance, the landmark data, gaps in evidence and seeks to provide practical guidance.
Prof Philippe Gabriel Steg (Hospital Bichat-Claude Bernard, FR) chairs the proceedings, and is joined by Dr Marc Bonaca (University of Colorado School of Medicine, US) and Dr Deepak Bhatt (Brigham and Women's Hospital, US) for a series of insightful presentations and discussions.
Catch up now on the other broadcasts in this series:
Key Learning Objectives
Following the completion of this programme, physicians will be in a position to:
- Discuss the disease burden in both primary and secondary prevention patients with high-risk features
- Identify clinical features that make CCS patients high risk
- Choose an appropriate antiplatelet regimen for CCS patients based on relevant history and current risk profile
- Recall the results of RCTs using potent P2Y12 inhibitors in CCS patients with a prior MI and in patients with existing diabetes, with/without MI
Target Audience
- General Cardiologists
- Interventional Cardiologists
- Nurses and any other allied HCPs
More from this programme
Part 1
Unmet Needs in CCS
| 1 session | |
| Unmet Needs in CCS | Watch now |
Part 2
Risk Mitigation in High and Very High-Risk Patients: What Does the Data Say?
Part 3
Prevention in Diabetes
| 1 session | |
| Prevention in Diabetes | Watch now |
Part 4
Long-term Management of CCS
| 1 session | |
| Long-term Management of CCS | Watch now |
Part 5
Q&A and Discussion
| 1 session | |
| Q&A and Discussion | Watch now |
Faculty Biographies
Philippe Gabriel Steg
Interventional Cardiologist
Prof Philippe Gabriel Steg works as an Interventional Cardiologist and is Director of the Coronary Care Unit of Hôpital Bichat, in Paris, France.
Prof Steg’s research interests are in the field of coronary artery disease. He is a former member of the Board of the French Society of Cardiology, an honorary member of the Institut Universitaire de France, and received the silver medal of the European Society of Cardiology in 2011.
Prof Steg led the TAO and EUROMAX trials and is chairing or co-chairing several trials or registries, such as ODYSSEY-CV Outcomes, CLARIFY, THEMIS. Prof Steg has authored more than 650 articles in peer-reviewed international journals. He is a member of the editorial boards for Circulation, Circulation: Cardiovascular Interventions, the European Heart Journal, and the European Heart Journal – Cardiovascular Pharmacotherapy. He is deputy editor for the…